Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

Feb 21 2020

• By Bridget Silverman

Keeping Track Feature image

Related Content

EU & US At Odds Over Merck’s Keytruda

Feb 20 2020

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

Jan 25 2020

Keeping Track Of The US FDA's Final Novel Approvals, CRLs Of 2019

Jan 05 2020

Ex-US FDA Director John Jenkins Sketches Regulatory Path For Esperion's Bempedoic Acid

Jul 11 2018

Twirla Gets Strong Advisory Cmte. Endorsement Even After US FDA Pans Application

Oct 31 2019

Keeping Track: US FDA, Industry Roar Into Fourth Quarter With Bevy Of Regulatory Announcements

Oct 06 2019

Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam

Mar 24 2019

Related Companies

Esperion Therapeutics, Inc.

Merck & Co., Inc.

Genentech, Inc.

Epizyme, Inc.

Seagen Inc.

Astellas Pharma, Inc.

Societal CDMO, Inc.

Heron Therapeutics, Inc.

Agile Therapeutics, Inc.

Viatris Inc.

Johnson & Johnson

Sebela Pharmaceuticals, Inc.

Additional Topics

United States Drug Review Approvals Drug Approval Standards Complete Response Letters US FDA Performance Tracker BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window